Apellis Pharmaceuticals (APLS)
(Delayed Data from NSDQ)
$49.86 USD
+1.93 (4.03%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $49.83 -0.03 (-0.06%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Price, Consensus and EPS Surprise
APLS 49.86 +1.93(4.03%)
Will APLS be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for APLS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for APLS
Apellis Pharmaceuticals (APLS) Down 8.7% Since Last Earnings Report: Can It Rebound?
Apellis (APLS) Q4 Earnings Miss, Revenues Meet Estimates
APLS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Apellis Pharmaceuticals, Inc. (APLS) Reports Q4 Earnings: What Key Metrics Have to Say
The Zacks Analyst Blog Highlights HEICO, Constellation Energy, Inter Parfums, Apellis Pharmaceuticals and Vaxcyte
Apellis Pharmaceuticals, Inc. (APLS) Reports Q4 Loss, Lags Revenue Estimates
Other News for APLS
Buy Rating Affirmed for Apellis Pharmaceuticals Amid Positive Outlook and Growth Potential
Apellis Announces Pegcetacoplan MAA Review Has Been Reset to Day 180 of Initial Assessment by European Medicines Agency (EMA)
Apellis announces pegcetacoplan MAA review has been reset to Day 180
Analysts Have Conflicting Sentiments on These Healthcare Companies: Apellis Pharmaceuticals (APLS), Quest Diagnostics (DGX) and Healthcare Services (HCSG)
Impact of Izervay’s Growth on Apellis Pharmaceuticals: Maintaining a Hold Rating Amidst Rising Competition